We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates
Read MoreHide Full Article
Inogen (INGN - Free Report) reported first-quarter 2020 loss per share of 7 cents, which was narrower than the Zacks Consensus Estimate of a loss of 10 cents. This compares to earnings of 24 cents in the year-ago quarter.
Revenues came in at $88.5 million, which surpassed the Zacks Consensus Estimate by 6.7%. On a year-over-year basis, the top line dropped 1.9%.
Segmental Details
Revenues at the Sales segment amounted to $83.1 million in the quarter under review, down 2% on a year-over-year basis.
Rental revenues grossed $5.34 million, down 0.7% year over year.
Revenues by Region & Category
Business-to-business revenues in the United States amounted to $27.6 million, up 5.7% on a year-over-year basis. Per management, this increase was primarily driven by increased home medical equipment provider demand.
Internationally, this segment recorded revenues of $20 million, up 1.4% year over year and 3.6% at constant currency. Per management, the increase was primarily led by higher demand in Canada and Australia.
Direct-to-consumer revenues fell 8.9% year over year to $35.5 million in the quarter.This was due to an approximate 15% reduction in average sales representative headcount compared to the year-ago quarter.
In the first quarter, gross profit was $38.4 million, down 13.6% year over year. Gross margin came in at 43.4%, down a significant 588 basis points (bps).
Loss from operations in the quarter was $2.2 million against the year-ago quarter’s operating profit of $4.9 million.
Guidance
Due to uncertainty around impact of the COVID-19 on its business, the company has withdrawn its 2020 guidance, issued on Feb 25.
Wrapping Up
Inogen ended the first quarter on a strong note. The company reported growth in business-to-business international and domestic revenues in the quarter.Inogen expects the business-to-business arm to be a strong contributor to revenues in 2020, thanks to the Tidal Assist Ventilator.
On the flip side, significant contraction in gross margin adds to the woes. Also, decline in direct-to-consumer revenues during the quarter is another concern. The company also saw a decline in Sales and Rental segment revenues.
Aphria reported third-quarter fiscal 2020 adjusted EPS of 2 cents, comparing favorably with the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million outpaced the consensus estimate by 14.6%. The company carries a Zacks Rank #2 (Buy) at present.
Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly delivered first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates
Inogen (INGN - Free Report) reported first-quarter 2020 loss per share of 7 cents, which was narrower than the Zacks Consensus Estimate of a loss of 10 cents. This compares to earnings of 24 cents in the year-ago quarter.
Revenues came in at $88.5 million, which surpassed the Zacks Consensus Estimate by 6.7%. On a year-over-year basis, the top line dropped 1.9%.
Segmental Details
Revenues at the Sales segment amounted to $83.1 million in the quarter under review, down 2% on a year-over-year basis.
Rental revenues grossed $5.34 million, down 0.7% year over year.
Revenues by Region & Category
Business-to-business revenues in the United States amounted to $27.6 million, up 5.7% on a year-over-year basis. Per management, this increase was primarily driven by increased home medical equipment provider demand.
Internationally, this segment recorded revenues of $20 million, up 1.4% year over year and 3.6% at constant currency. Per management, the increase was primarily led by higher demand in Canada and Australia.
Direct-to-consumer revenues fell 8.9% year over year to $35.5 million in the quarter.This was due to an approximate 15% reduction in average sales representative headcount compared to the year-ago quarter.
Inogen, Inc Price, Consensus and EPS Surprise
Inogen, Inc price-consensus-eps-surprise-chart | Inogen, Inc Quote
Margins
In the first quarter, gross profit was $38.4 million, down 13.6% year over year. Gross margin came in at 43.4%, down a significant 588 basis points (bps).
Loss from operations in the quarter was $2.2 million against the year-ago quarter’s operating profit of $4.9 million.
Guidance
Due to uncertainty around impact of the COVID-19 on its business, the company has withdrawn its 2020 guidance, issued on Feb 25.
Wrapping Up
Inogen ended the first quarter on a strong note. The company reported growth in business-to-business international and domestic revenues in the quarter.Inogen expects the business-to-business arm to be a strong contributor to revenues in 2020, thanks to the Tidal Assist Ventilator.
On the flip side, significant contraction in gross margin adds to the woes. Also, decline in direct-to-consumer revenues during the quarter is another concern. The company also saw a decline in Sales and Rental segment revenues.
Zacks Rank and Key Picks
Inogen currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Aphria Inc. , Biogen Inc. (BIIB - Free Report) and Eli Lilly and Company (LLY - Free Report) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aphria reported third-quarter fiscal 2020 adjusted EPS of 2 cents, comparing favorably with the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million outpaced the consensus estimate by 14.6%. The company carries a Zacks Rank #2 (Buy) at present.
Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly delivered first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>